MAGE-D2 Inhibitors
MAGE-D2 inhibitors belong to a specific chemical class designed to target the MAGE-D2 protein, a member of the melanoma-associated antigen (MAGE) family. The MAGE proteins, originally identified in melanoma cells, have been implicated in various cellular processes, including cell growth, differentiation, and apoptosis. MAGE-D2, in particular, is recognized for its overexpression in several cancer types, indicating its potential involvement in tumorigenesis. The inhibitors are meticulously crafted to interfere with the activity of MAGE-D2, potentially disrupting its cellular functions and, by extension, impeding the progression of associated malignancies.
These inhibitors typically exert their effects through intricate molecular interactions with the MAGE-D2 protein. The chemical structures of MAGE-D2 inhibitors are designed to complement the binding pocket of the protein, forming stable complexes that interfere with the normal functioning of MAGE-D2. By disrupting the protein's activity, these inhibitors aim to modulate downstream signaling pathways and cellular processes implicated in cancer development. The development of MAGE-D2 inhibitors represents a targeted approach in the realm of chemical biology, where understanding the structural and functional aspects of specific proteins allows for the design of small molecules with the potential to selectively intervene in disease-related processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal metabolite inhibitor of phosphoinositide 3-kinases (PI3K) which can affect downstream signaling pathways that may intersect with MAGED2-related processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic molecule functioning as a PI3K inhibitor, potentially affecting pathways where MAGED2 is implicated. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide compound that inhibits mTOR, a key kinase that may interact with MAGED2's pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is a synthetic compound that inhibits Akt, a serine/threonine-specific protein kinase that could be involved in MAGED2's signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that inhibits MEK, which may indirectly affect MAGED2 through the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), potentially modulating signaling pathways involving MAGED2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that inhibits p38 MAP kinase, which could indirectly influence MAGED2 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK), which may be part of the regulatory processes of MAGED2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect multiple cellular processes, potentially including those associated with MAGED2. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a sesquiterpene lactone that disrupts calcium homeostasis in cells, possibly affecting MAGED2-related functions. | ||||||